论文部分内容阅读
目的观察普米克令舒加博利康尼雾化吸入治疗支原体肺炎的疗效。方法将确诊为支原体肺炎患儿186例随机用双盲法分观察组95例和对照组91例,两组按照常规用大环内酯类治疗处理基础上,对照组用硫酸沙丁胺醇溶液和异丙托溴胺溶液雾化吸入治疗,观察组用普米克令舒加博利康尼雾化吸入治疗,5 d为一疗程。结果观察组与对照组治愈率分别为87%、68%,两组治疗效果比较差异有统计学意义。结论普米克令舒加博利康尼雾化吸入治疗支原体肺炎治疗效果好。
Objective To observe the curative effect of Pulmicort Respubrially Pulverizan inhalation in the treatment of mycoplasma pneumonia. Methods A total of 186 children with mycoplasma pneumonia who were diagnosed as mycoplasmal pneumonia were randomly divided into two groups: 95 cases in the observation group and 91 cases in the control group. According to the conventional treatment with macrolides, the patients in the control group were treated with salbutamol sulfate and isopropyl Tuomo bromide solution inhalation therapy, the observation group with Pulmicort Respubliolib aerosol inhalation therapy, 5 d for a course of treatment. Results The cure rates of the observation group and the control group were 87% and 68%, respectively, and the difference between the two groups was statistically significant. Conclusions Pulmicort respules subconjunctival aerosol inhalation of mycoplasma pneumonia is effective.